Xeroderma Pigmentosum Variant (XP-V) - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱ 6 min read ✅ Medically reviewed
```html Xeroderma Pigmentosum Variant (XP‑V) – Comprehensive Guide

Xeroderma Pigmentosome Variant (XP‑V) – A Complete Patient Guide

Overview

Xeroderma pigmentosum variant (XP‑V) is a rare, inherited disorder that impairs the body’s ability to repair DNA damage caused by ultraviolet (UV) light. Unlike the classic forms of xeroderma pigmentosum (XP), which are caused by defects in the nucleotide‑excision repair (NER) pathway, XP‑V results from a mutation in the POLH gene that encodes DNA polymerase η, an enzyme responsible for “bypass” synthesis past UV‑induced lesions.

  • Who it affects: Autosomal recessive inheritance means a child must receive a faulty copy of POLH from each parent. Both males and females are equally affected.
  • Prevalence: XP overall occurs in roughly 1 per 1 000 000–1 200 000 live births worldwide, with XP‑V accounting for ~10–15 % of those cases (CDC; Mayo Clinic). Certain populations with founder mutations—e.g., parts of North Africa, the Middle East, and Japan—show higher frequencies.
  • Age of presentation: Most individuals notice skin changes before age 10, although the disease can be identified later through genetic testing.

Symptoms

Because XP‑V primarily hampers UV‑damage tolerance, the clinical picture centers on photosensitivity and skin changes. However, the phenotype can be milder than classic XP.

Cutaneous manifestations

  • Photosensitivity: Burning or erythema after minimal sun exposure (often within minutes).
  • Freckling & hyperpigmentation: Numerous lentigines on sun‑exposed areas (face, neck, forearms).
  • Actinic keratoses: Rough, scaly patches that may develop into skin cancer if untreated.
  • Skin cancers: Basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and, less commonly, melanoma—typically appearing in the second‑to‑third decade of life. In XP‑V, the onset is usually later than in other XP subtypes.
  • Premature skin aging: Wrinkling and loss of elasticity in sun‑exposed skin.

Ocular manifestations

  • Photophobia: Discomfort or pain in bright light.
  • Conjunctival inflammation (pinguecula, pterygium).
  • Corneal opacities or ulceration from chronic UV injury.
  • Increased risk of ocular surface neoplasia (SCC of the eyelid or conjunctiva).

Neurologic & systemic features

Neurologic degeneration is rare in XP‑V (seen in ≀5 % of cases) but can include mild motor coordination problems. Unlike classic XP, most patients retain normal cognitive development.

Causes and Risk Factors

Genetic cause

XP‑V is caused by biallelic pathogenic variants in the POLH gene (located on chromosome 6p21.1). The most common mutation is a single‑base substitution leading to a non‑functional DNA polymerase η.

Inheritance pattern

  • Autosomal recessive – each parent is an asymptomatic carrier.
  • Carrier frequency varies; in some isolated communities it can be as high as 1 in 70.

Environmental risk factors

  • High cumulative UV exposure (living near the equator, outdoor occupations, outdoor recreation without protection).
  • Use of photosensitizing medications (e.g., tetracyclines, certain antifungals) can worsen photosensitivity.

Other risk modifiers

  • Fair skin, light eye color, and a history of sunburns increase the likelihood of early skin lesions.
  • Immunosuppression (organ transplant, HIV) may accelerate cancer development.

Diagnosis

Clinical evaluation

Diagnosis begins with a detailed history of photosensitivity, skin lesions, and family history, followed by a thorough skin and eye examination.

Laboratory & genetic testing

  • DNA repair assays: Cellular tests (e.g., unscheduled DNA synthesis) can demonstrate reduced UV‑damage tolerance.
  • Targeted gene panel or whole‑exome sequencing: Detects pathogenic POLH variants. This is the gold‑standard test.
  • Carrier testing: Recommended for siblings of an affected individual and for couples planning a pregnancy.

Additional investigations

  • Dermoscopic evaluation of suspicious lesions.
  • Ophthalmologic slit‑lamp exam and fundus photography.
  • Routine skin biopsies when malignancy is suspected.

Treatment Options

There is no cure for XP‑V; management focuses on preventing UV‑induced damage and treating skin lesions early.

Sun‑protection measures (first‑line)

  • Broad‑spectrum sunscreen: SPF ≄ 50, reapplied every 2 hours and after swimming or sweating.
  • Protective clothing: UPF‑rated shirts, wide‑brim hats, UV‑blocking sunglasses.
  • Physical barriers: UV‑filtering window films for homes and cars.

Pharmacologic therapies

  • Topical 5‑fluorouracil or imiquimod: Used to treat actinic keratoses and superficial skin cancers.
  • Systemic retinoids (e.g., acitretin): May reduce the number of new premalignant lesions but require monitoring for liver toxicity and lipid changes.
  • Oral nicotinamide: Emerging evidence suggests it can enhance DNA repair and reduce non‑melanoma skin cancer incidence (JAMA Dermatology, 2018).

Surgical and procedural interventions

  • Excision of BCC, SCC, or melanoma with clear margins.
  • Cryotherapy or photodynamic therapy for superficial lesions.
  • Regular ophthalmologic procedures (e.g., limbal stem‑cell transplantation) for severe corneal disease.

Lifestyle & supportive care

  • Vitamin D supplementation (sun avoidance often leads to deficiency).
  • Psychological counseling to address social isolation and anxiety about cancer risk.
  • Genetic counseling for the patient and family.

Living with Xeroderma Pigmentosum Variant (XP‑V)

Daily management tips

  1. Morning sunscreen routine: Apply Πteaspoon per fingertip area to face, neck, and arms before leaving home.
  2. Plan outdoor activities: Schedule them before 10 a.m. or after 4 p.m. when UV index is lower.
  3. Clothing checklist: Long‑sleeve shirt, pants, UV‑blocking gloves, and a wide‑brim hat.
  4. Skin self‑exams: Perform a thorough inspection weekly; use a mirror for hard‑to‑see areas.
  5. Maintain a skin‑lesion diary: Photograph new or changing spots and bring records to dermatology appointments.
  6. Eye protection: Wear wrap‑around sunglasses with 100 % UV‑A/B blocking; consider photochromic lenses for indoor use.
  7. Education: Teach school staff and caregivers about the need for protective measures.
  8. Nutrition: Eat a diet rich in antioxidants (berries, leafy greens) which may help mitigate oxidative DNA damage.

Support resources

  • XP Patient Registry – xpregistry.org
  • National Organization for Rare Disorders (NORD) – information and patient‑advocacy groups.
  • Psychology hotlines and support groups for chronic skin‑cancer survivors.

Prevention

Because the genetic defect cannot be reversed, “prevention” refers to minimizing UV exposure and early detection of lesions.

  • Consistent use of high‑SPF sunscreen and protective clothing.
  • Installation of UV‑filtering window films at home, work, and vehicles.
  • Avoid tanning beds—these emit intense UV radiation.
  • Annual full‑body skin exams by a dermatologist experienced with XP.
  • Regular ophthalmology check‑ups (at least once a year).
  • Vaccination against human papillomavirus (HPV) – reduces risk of HPV‑related skin cancers.

Complications

If UV protection is inadequate, several serious complications can arise:

  • Multiple non‑melanoma skin cancers: BCC and SCC can become invasive, requiring extensive surgery or radiation.
  • Melanoma: Higher mortality risk; early detection is critical.
  • Vision loss: Corneal scarring, cataracts, or ocular surface cancers may lead to blindness.
  • Psychosocial impact: Chronic disease burden can cause depression, social withdrawal, and reduced quality of life.
  • Vitamin D deficiency: Persistent sun avoidance can lead to bone health problems if not supplemented.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Rapidly spreading ulcerated skin lesion with uncontrolled bleeding.
  • Sudden vision loss, severe eye pain, or a white/gray spot on the cornea (possible ulcer or infection).
  • Severe sunburn that causes blistering over a large body area, fever, chills, or signs of infection.
  • Persistent, high‑grade fever with a painful skin nodule (possible necrotizing infection).
Prompt evaluation can prevent life‑threatening complications and preserve vision.

**References**

  1. Mayo Clinic. Xeroderma pigmentosum. https://www.mayoclinic.org. Accessed April 2026.
  2. Centers for Disease Control and Prevention. Xeroderma Pigmentosum Fact Sheet. https://www.cdc.gov. Updated 2023.
  3. World Health Organization. UV Radiation and Health. https://www.who.int. 2022.
  4. Johnson, D. et al. “POLH mutations and the clinical spectrum of XP‑V.” *Journal of Investigative Dermatology* 140, 2021: 1245‑1253.
  5. Harper, J.C. et al. “Nicotinamide for skin‑cancer chemoprevention.” *JAMA Dermatology* 154(8), 2018: 858‑866. DOI:10.1001/jamadermatol.2018.0204.
  6. Cleveland Clinic. Xeroderma pigmentosum: Diagnosis & treatment. https://my.clevelandclinic.org. Accessed 2026.
```

⚠ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References